| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
|
Nesteryuk, Vasyl
|
|
|
23 |
8 |
p. e550-e555
|
artikel
|
| 2 |
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases
|
Itchins, Malinda
|
|
|
23 |
8 |
p. 702-708
|
artikel
|
| 3 |
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11)
|
Kim, Kyung Hwan
|
|
|
23 |
8 |
p. e536-e539
|
artikel
|
| 4 |
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
|
Zhou, Li
|
|
|
23 |
8 |
p. 709-719
|
artikel
|
| 5 |
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
|
Ahn, Myung-Ju
|
|
|
23 |
8 |
p. 670-685
|
artikel
|
| 6 |
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
|
Shah, Mohsin
|
|
|
23 |
8 |
p. 731-736
|
artikel
|
| 7 |
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
|
Guisier, Florian
|
|
|
23 |
8 |
p. e545-e549
|
artikel
|
| 8 |
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer
|
Yu, Nathan Y.
|
|
|
23 |
8 |
p. e526-e535
|
artikel
|
| 9 |
Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report
|
Owen, Timothy
|
|
|
23 |
8 |
p. e563-e567
|
artikel
|
| 10 |
Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
|
Banks, Kian C.
|
|
|
23 |
8 |
p. 694-701
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
23 |
8 |
p. A1
|
artikel
|
| 12 |
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
|
Ahn, Myung J.
|
|
|
23 |
8 |
p. 720-730
|
artikel
|
| 13 |
Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events
|
Guo, Mengni
|
|
|
23 |
8 |
p. 686-693
|
artikel
|
| 14 |
Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options
|
Leal, Jose Luis
|
|
|
23 |
8 |
p. 643-658
|
artikel
|
| 15 |
Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis
|
Kuang, Yuting
|
|
|
23 |
8 |
p. 659-669
|
artikel
|
| 16 |
Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis
|
Maller, Bradley
|
|
|
23 |
8 |
p. e519-e525
|
artikel
|
| 17 |
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
|
Wang, Pascal
|
|
|
23 |
8 |
p. e568-e572
|
artikel
|
| 18 |
Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis
|
Alnimer, Yanal
|
|
|
23 |
8 |
p. e510-e518
|
artikel
|
| 19 |
Table of Contents
|
|
|
|
23 |
8 |
p. A3-A6
|
artikel
|
| 20 |
Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis
|
Pevner, Justin L.
|
|
|
23 |
8 |
p. e540-e544
|
artikel
|
| 21 |
The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX)
|
Bang, Tami J.
|
|
|
23 |
8 |
p. e501-e509
|
artikel
|
| 22 |
U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome
|
Kaland, David A.
|
|
|
23 |
8 |
p. e556-e562
|
artikel
|
Tijdschrift beschrijving